Reports and Insights (R&I) has published a new report titled, “Gaucher Disease Drugs Market: Opportunity Analysis And Future Assessment 2020 To 2028”
Global Gaucher Disease Drugs Market, by Type (Type 1, Type 2, and Type 3), by Therapy (Enzyme Replacement Therapy and Substrate Replacement Therapy) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.
The global gaucher disease drugs market in 2020 is estimated for more than US$ 1.2 Bn and expected to reach a value of US$ 1.4 Bn by 2028 with a significant CAGR of 1.5%
Gaucher disease refers to a state of disorder of gene, where the body fat gets accumulated into the tissues or certain organs. It is mainly caused by the deficiency of an enzyme, named B-glucocerebrosidase; this state can further result into fatigue, low blood platelet count, bruising, etc. this disease is also characterized by the enlargement of the liver and spleen and is more likely to affect children than adults. As per the report, the elevated demand for efficient and well-controlled treatment is the prime factor driving market growth.
Also, factors like elevated count of developed drugs and their approvals, growing efforts for the identification of patients suffering from Gaucher disease, increasing disposable income, etc. are also responsible for favouring the Gaucher disease drug market during the upcoming years.
Moreover, increasing the government’s initiatives to promote awareness about this disease also stimulates the market growth; like the European Gaucher Alliance launched a Gaucher awareness day to acknowledge their citizens about Gaucher and its effects.
However, the rare nature of the Gaucher disease along with the high cost associated with its treatment are likely to restrain the growth of the global Gaucher disease drug market.
Furthermore, Reports and Insights (R&I) Study identifies that the collaborations of the prominent market players for the upcoming research studies for the optimization of appropriate dosage are favourable for the market growth. This tie-up will result in the development of improved drugs that will combat Gaucher disease at reduced costs. This will also result in a convenient administration schedule, improving the management of this rare disease.
Besides, the strong commercialization of enzyme replacement therapy including Cerezyme, Vpriv, and Elelyso will also boost the demand for Gaucher disease drugs during the upcoming years. In addition, the increasing count of FDA approved drugs for treating Gaucher disease is also responsible for dominating enzyme replacement therapy segment.
Global Gaucher disease drug market is segmented into three sections, namely, by type, therapy, and region. On the basis of type, this market is fragmented into Type 1, Type 2, and Type 3. Whereas, the therapy segment is sectioned as Enzyme Replacement Therapy and Substrate Replacement Therapy. Lastly, on the basis of regions, this market is divided into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
R&I Study also identifies some of the key participating players of Gaucher disease drugs market globally as Sanofi Genzyme, Shire Human Genetic Therapies, Inc., Pfizer, Inc., and Johnson & Johnson.
Reports and Insights (R&I) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Reports and Insights (R&I)
For Sales Queries: [email protected]
For New Topics and Other Info: [email protected]